肺がん診断テスト:医療機器パイプライン分析

◆英語タイトル:Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0193
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:555
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD8,000 ⇒換算¥880,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD12,000 ⇒換算¥1,320,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Lung Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Lung Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2019″ provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Lung Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 15
1.2 List of Figures 24
2 Introduction 25
2.1 Lung Cancer Diagnostic Tests Overview 25
3 Products under Development 26
3.1 Lung Cancer Diagnostic Tests – Pipeline Products by Stage of Development 26
3.2 Lung Cancer Diagnostic Tests – Pipeline Products by Territory 27
3.3 Lung Cancer Diagnostic Tests – Pipeline Products by Regulatory Path 28
3.4 Lung Cancer Diagnostic Tests – Pipeline Products by Estimated Approval Date 29
3.5 Lung Cancer Diagnostic Tests – Ongoing Clinical Trials 30
4 Lung Cancer Diagnostic Tests – Pipeline Products under Development by Companies 31
4.1 Lung Cancer Diagnostic Tests Companies – Pipeline Products by Stage of Development 31
4.2 Lung Cancer Diagnostic Tests – Pipeline Products by Stage of Development 36
5 Lung Cancer Diagnostic Tests Companies and Product Overview 41
6 Lung Cancer Diagnostic Tests – Recent Developments 220
7 Appendix 540

List of Tables
Table 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
Table 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
Table 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
Table 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
Table 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30
Table 6: Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 31
Table 7: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 36
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 9: Onco 88 - Lung Cancer Diagnostic Tests - Product Status 41
Table 10: Onco 88 - Lung Cancer Diagnostic Tests - Product Description 41
Table 11: OncoStain 88 - Lung Cancer Diagnostic Tests - Product Status 42
Table 12: OncoStain 88 - Lung Cancer Diagnostic Tests - Product Description 42
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 43
Table 14: ARCHITECT c4000 System - NSE Assay - Product Status 43
Table 15: ARCHITECT c4000 System - NSE Assay - Product Description 44
Table 16: ARCHITECT c8000 System - NSE Assay - Product Status 44
Table 17: ARCHITECT c8000 System - NSE Assay - Product Description 44
Table 18: ARCHITECT ci4100 Integrated System - NSE Assay - Product Status 45
Table 19: ARCHITECT ci4100 Integrated System - NSE Assay - Product Description 45
Table 20: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status 45
Table 21: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description 46
Table 22: ARCHITECT i1000SR System - NSE Assay - Product Status 46
Table 23: ARCHITECT i1000SR System - NSE Assay - Product Description 46
Table 24: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Status 47
Table 25: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Description 47
Table 26: PRAME Antigen Lung Cancer Assay - Product Status 47
Table 27: PRAME Antigen Lung Cancer Assay - Product Description 48
Table 28: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 49
Table 29: Diagnostic Assay - Lung Cancer Diagnostic Tests - Product Status 49
Table 30: Diagnostic Assay - Lung Cancer Diagnostic Tests - Product Description 49
Table 31: MCM Test - Lung Cancer Diagnostic Tests - Product Status 50
Table 32: MCM Test - Lung Cancer Diagnostic Tests - Product Description 50
Table 33: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview 51
Table 34: Diagnostic Biomarker Test - Lung Cancer Diagnostic Tests - Product Status 51
Table 35: Diagnostic Biomarker Test - Lung Cancer Diagnostic Tests - Product Description 51
Table 36: Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview 52
Table 37: Diagnostic Test - ACTN4 - Product Status 52
Table 38: Diagnostic Test - ACTN4 - Product Description 53
Table 39: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 54
Table 40: Companion Diagnostic Test - Lung Cancer Diagnostic Tests - Product Status 54
Table 41: Companion Diagnostic Test - Lung Cancer Diagnostic Tests - Product Description 54
Table 42: Diagnostic/Prognostic Assay - Lung Cancer Diagnostic Tests - Product Status 55
Table 43: Diagnostic/Prognostic Assay - Lung Cancer Diagnostic Tests - Product Description 55
Table 44: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 56
Table 45: DiagnoLung - Product Status 56
Table 46: DiagnoLung - Product Description 56
Table 47: Predictive Diagnostic Test - Lung Cancer Diagnostic Tests - Product Status 57
Table 48: Predictive Diagnostic Test - Lung Cancer Diagnostic Tests - Product Description 57
Table 49: Prognostic Test - Lung Cancer Diagnostic Tests - Product Status 57
Table 50: Prognostic Test - Lung Cancer Diagnostic Tests - Product Description 58
Table 51: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 59
Table 52: Biomarker Assay - Lung Cancer Diagnostic Tests - Product Status 59
Table 53: Biomarker Assay - Lung Cancer Diagnostic Tests - Product Description 59
Table 54: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
Table 55: Prognostic Test - Early Stage Lung Cancer Diagnostic Tests - Product Status 60
Table 56: Prognostic Test - Early Stage Lung Cancer Diagnostic Tests - Product Description 60
Table 57: Prognostic Test - NSCLC - Product Status 61
Table 58: Prognostic Test - NSCLC - Product Description 61
Table 59: ANGLE plc Pipeline Products & Ongoing Clinical Trials Overview 62

List of Figures
Figure 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
Figure 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
Figure 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
Figure 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
Figure 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肺がん診断テスト:医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆